Skip to content

Amnioinfusion Initiative

Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00787163
Enrollment
82
Registered
2008-11-07
Start date
2008-09-30
Completion date
2013-12-31
Last updated
2009-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligohydramnios

Keywords

pPROM, oligohydramnios, amnioinfusion, prematurity, Early premature rupture of membranes in pregnancy

Brief summary

The aim of this study is to compare perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions.

Detailed description

Early spontaneous Preterm Premature Rupture of Membranes (PPROM) is associated with high perinatal mortality. Due to pulmonary hypoplasia and preterm delivery, mortality exceeds 60% when PPROM occurs prior to 24 weeks. When oligohydramnios persists, it may raise to 90%. Morbidity in survivors is also significant. In uncontrolled series, serial amnioinfusions, which have acceptable invasiveness and are of limited complexity, mortality was reduced to 60%. We propose an open, multicenter randomized trial comparing perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions. Inclusion criteria: Single pregnancy, early spontaneous PPROM \< 24.3 weeks, oligohydramnios (deepest vertical pocket \< 2 cm) for at least 4 days and no longer than 15 days at enrolment. The study is open and will be run through a dedicated password protected web site, and with a minimal number of outcome measures. Primary outcome: Survival till discharge from the NICU. Secondary outcomes: Latency time from PPROM to delivery, gestational age at birth, indication for delivery, number of days of ventilatory support, serious neurologic morbidity, neonatal sepsis prevalence, need for oxygen at 36 weeks post-conception.

Interventions

PROCEDUREamnioinfusion

serial amnioinfusions aimed at restoring amniotic fluid volume

Sponsors

KU Leuven
CollaboratorOTHER
University of Milan
CollaboratorOTHER
Catholic University, Italy
CollaboratorOTHER
Università degli Studi di Brescia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Patients above 18 years, who are able to consent, with 2. Singleton pregnancy 3. with a normal structural examination as much as possible; 4. At least 2 US examination after pPROM for gestational age confirmation and diagnosis of persistent oligohydramnios 5. Follow up ultrasound examinations weekly in the treatment group 6. Acceptance of randomisation and to comply with the protocol

Exclusion criteria

1. Maternal contra-indications to intervention or prolongation of pregnancy, including severe medical conditions in pregnancy that make fetal intervention riskful; 2. Preterm labour defined as contractions \>6/hour associated with cervical changes, cervix shortened (\<15 mm at randomization), 3. Cervical cerclage in place 4. Chorioamnionitis, defined as 2 or more of the following: maternal temperature\>38 degrees, foul-smelling vaginal discharge, uterine tenderness, fetal tachycardia\>170 bpm, white blood cell count \>18,000 5. Fetal structural anomaly detected at prenatal ultrasonography, or fetal chromosomal abnormalities involving autosomes 6. Previous invasive procedure in this index pregnancy 7. Fetal condition mandating immediate delivery 8. Severe bleeding 9. Maternal HIV and HCV infection 10. Multiple gestation

Design outcomes

Primary

MeasureTime frame
Survival of neonates/infants at discharge after serial amnioinfusions compared to survival after expectant managementdischarge of every neonate from NICU

Secondary

MeasureTime frame
Gestational age of delivery (main secondary outcome)time of delivery for every case

Countries

Italy

Contacts

Primary ContactAnna Locatelli, MD
anna.locatelli@unimib.it+39 039 233 4720

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026